<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39349578</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Fabrication of mRNA encapsulated lipid nanoparticles using state of the art SMART-MaGIC technology and transfection in vitro.</ArticleTitle><Pagination><StartPage>22714</StartPage><MedlinePgn>22714</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22714</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-73804-y</ELocationID><Abstract><AbstractText>The messenger ribose nucleic acid (mRNA) in the form of Corona virus of 2019 (COVID-19) vaccines were effectively delivered through lipid nanoparticles (LNP) proving its use as effective carriers in clinical applications. In the present work, mRNA (erythropoietin (EPO)) encapsulated LNPs were prepared using a next generation state-of-the-art patented, Sprayed Multi Absorbed-droplet Reposing Technology (SMART) coupled with Multi-channeled and Guided Inner-Controlling printheads (MaGIC) technologies. The LNP-mRNA were synthesized at different N/P ratios and the particles were characterized for particle size and zeta potential (Zetasizer), encapsulation or complexation (gel retardation assay) and transfection (Fluorescence microscopy and ELISA) in MG63 sarcoma cells in vitro. The results showed a narrow distribution of mRNA-lipid particles of 200 nm when fabricated with SMART alone and then the size was reduced to approximately 50 nm with the combination of SMART-MaGIC technologies. The gel retardation assay showed that the N/P &gt; 1 exhibited strong encapsulation of mRNA with lipid. The in vitro results showed the toxicity profile of the lipids where N/P ratio of 5 was optimized with &gt; 50% cell viability. It can be concluded that the functional LNP-mRNA prepared and analyzed with SMART-MaGIC technologies, could be a potential new fabrication method of mRNA loaded LNPs for point-of-service or distributed manufacturing.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Heshmati</LastName><ForeName>Niloofar</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chakka</LastName><ForeName>Leela Raghava Jaidev</ForeName><Initials>LRJ</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaceutical Engineering and 3D Printing (PharmE3D) Lab, Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaceutical Engineering and 3D Printing (PharmE3D) Lab, Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maniruzzaman</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA. mmaniruz@olemiss.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaceutical Engineering and 3D Printing (PharmE3D) Lab, Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA. mmaniruz@olemiss.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 FD007456</GrantID><Acronym>FD</Acronym><Agency>FDA HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01FD007456-01</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000711949">Lipid Nanoparticles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="Y">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="Y">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="Y">Lipids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">And Erythropoietin</Keyword><Keyword MajorTopicYN="N">Gene delivery</Keyword><Keyword MajorTopicYN="N">Lipid nanoparticles</Keyword><Keyword MajorTopicYN="N">Messenger RNA</Keyword><Keyword MajorTopicYN="N">SMART technology</Keyword><Keyword MajorTopicYN="N">mRNA therapeutics</Keyword></KeywordList><CoiStatement>All the authors, Niloofar Heshmati (N.H.), Leela Raghava Jaidev Chakka (L.C.), Yu Zhang (Y.Z.) and Mohammed Maniruzzaman (M.M.) are co-inventors of related intellectual property (IP). M.M., an author of this manuscript, holds stock in, serves on a scientific advisory board for, or is a consultant for CoM3D Ltd. (Surrey, UK), DosePlus Therapeutics, Inc. (Princeton, NJ, USA), and Septum Solutions LLC (Houston, TX, USA). The terms of this arrangement have been reviewed and approved by the University of Texas at Austin and the University of Mississippi (Ole Miss) in accordance with their policies on objectivity in research. The companies had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; and in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>23</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39349578</ArticleId><ArticleId IdType="pmc">PMC11442764</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-73804-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-73804-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Webb, C. et al. Current status and future perspectives on MRNA drug manufacturing. Mol. Pharm.19(4), 1047–1058. 10.1021/acs.molpharmaceut.2c00010 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35238565</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli, G. et al. COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern. Med.180(10), 1345–1355. 10.1001/jamainternmed.2020.3539 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364371</ArticleId><ArticleId IdType="pubmed">32667669</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, X. et al. The landscape of mRNA nanomedicine. Nat. Med.28(11), 2273–2287. 10.1038/s41591-022-02061-1 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36357682</ArticleId></ArticleIdList></Reference><Reference><Citation>Hald Albertsen, C. et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv Rev.188, 114416. 10.1016/j.addr.2022.114416 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250827</ArticleId><ArticleId IdType="pubmed">35787388</ArticleId></ArticleIdList></Reference><Reference><Citation>Eygeris, Y., Gupta, M., Kim, J. &amp; Sahay, G. Chemistry of lipid nanoparticles for RNA delivery. Acc. Chem. Res.55(1), 2–12. 10.1021/acs.accounts.1c00544 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34850635</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou, X., Zaks, T., Langer, R. &amp; Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater.6(12), 1078–1094. 10.1038/s41578-021-00358-0 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8353930</ArticleId><ArticleId IdType="pubmed">34394960</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao, L. et al. Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver. Nat. Commun.11(1), 2424. 10.1038/s41467-020-16248-y (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7229004</ArticleId><ArticleId IdType="pubmed">32415122</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo, J. D. et al. Use of Epoetin and Darbepoetin in patients with Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. J. Clin. Oncol.26(1), 132–149. 10.1200/JCO.2007.14.3396 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17954713</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikó, K., Muramatsu, H., Keller, J. M. &amp; Weissman, D. Increased erythropoiesis in mice injected with Submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol. Ther.20(5), 948–953. 10.1038/mt.2012.7 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345990</ArticleId><ArticleId IdType="pubmed">22334017</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, S., Gao, H. &amp; Bao, G. Physical principles of nanoparticle cellular endocytosis. ACS Nano9(9), 8655–8671. 10.1021/acsnano.5b03184 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5681865</ArticleId><ArticleId IdType="pubmed">26256227</ArticleId></ArticleIdList></Reference><Reference><Citation>The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction | Nanomedicine. https://www.futuremedicine.com/doi/10.2217/nnm.16.5 (accessed 2023-10-25).</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nnm.16.5</ArticleId><ArticleId IdType="pmc">PMC5561790</ArticleId><ArticleId IdType="pubmed">27003448</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, H. W., Chow, S., Zhang, X., Kwok, P. C. L. &amp; Chow, S. F. Role of particle size in translational research of nanomedicines for successful drug delivery: Discrepancies and inadequacies. J. Pharm. Sci.112(9), 2371–2384. 10.1016/j.xphs.2023.07.002 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37453526</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeki, M., Uno, S., Niwa, A., Okada, Y. &amp; Tokeshi, M. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. J. Controlled Release344, 80–96. 10.1016/j.jconrel.2022.02.017 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8851889</ArticleId><ArticleId IdType="pubmed">35183654</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui, L., Pereira, S., Sonzini, S., Pelt, S. &amp; van Development of a high-throughput platform for screening lipid nanoparticles for mRNA delivery. Nanoscale14(4), 1480–1491. 10.1039/D1NR06858J (2022). RomanelliS. M.Liang, L.; Ulkoski, D.; Krishnamurthy, V. R.; Brannigan, E.; Brankin, C.; Desai, A. S.</Citation><ArticleIdList><ArticleId IdType="pubmed">35024714</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Brien Laramy, M. N. et al. Process robustness in lipid nanoparticle production: A comparison of Microfluidic and turbulent jet mixing. Mol. Pharm.20(8), 4285–4296. 10.1021/acs.molpharmaceut.3c00390 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11290355</ArticleId><ArticleId IdType="pubmed">37462906</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong, V. A., Nguyen, T. T. L. &amp; Maeng, H. J. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method. Molecules25(20), 4781. 10.3390/molecules25204781 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7587569</ArticleId><ArticleId IdType="pubmed">33081021</ArticleId></ArticleIdList></Reference><Reference><Citation>Aditya, N. P., Patankar, S., Madhusudhan, B., Murthy, R. S. R. &amp; Souto, E. B. Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: Pharmacokinetics, toxicological and in vivo anti-malarial activity. Eur. J. Pharm. Sci.40(5), 448–455. 10.1016/j.ejps.2010.05.007 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20493255</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassett, K. J. et al. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J. Controlled Release335, 237–246. 10.1016/j.jconrel.2021.05.021 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34019945</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, L., Bandara, S. R., Tan, Z. &amp; Leal, C. Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm. Proc. Natl. Acad. Sci.120(27), e2301067120. 10.1073/pnas.2301067120 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10318962</ArticleId><ArticleId IdType="pubmed">37364130</ArticleId></ArticleIdList></Reference><Reference><Citation>Beg, S., Almalki, W. H., Malik, A., Farhan, M., Aatif, M., Rahman, Z., Alruwaili, N. K., Alrobaian, M., Tarique, M., Rahman, M. 3D printing for drug delivery and biomedical applications. Drug Discov Today25(9), 1668–1681. 10.1016/j.drudis.2020.07.007 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32687871</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Dulimi, Z., Wallis, M., Tan, D. K., Maniruzzaman, M. &amp; Nokhodchi, A. 3D printing technology as innovative solutions for biomedical applications. Drug Discov .Today26(2), 360–383. 10.1016/j.drudis.2020.11.013 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33212234</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetsuka, H. &amp; Shin, S. R. Materials and technical innovations in 3D printing in biomedical applications. J. Mater. Chem. B8(15), 2930–2950. 10.1039/D0TB00034E (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092991</ArticleId><ArticleId IdType="pubmed">32239017</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz, V. M. &amp; Kumar, L. 3D printing as a promising tool in personalized medicine. AAPS PharmSciTech22(1), 49. 10.1208/s12249-020-01905-8 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811988</ArticleId><ArticleId IdType="pubmed">33458797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallis, M., Al-Dulimi, Z., Tan, D. K., Maniruzzaman, M. &amp; Nokhodchi, A. 3D Printing for enhanced drug delivery: Current state-of-the-art and challenges. Drug Dev. Ind. Pharm.46(9), 1385–1401. 10.1080/03639045.2020.1801714 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32715832</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J. et al. Emerging 3D printing technologies for drug delivery devices: Current status and future perspective. Adv. Drug Deliv Rev.174, 294–316. 10.1016/j.addr.2021.04.019 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33895212</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakka, L. R. J. &amp; Chede, S. 3D printing of pharmaceuticals for disease treatment. Front. Med. Technol.4 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9871616</ArticleId><ArticleId IdType="pubmed">36704231</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, K., Brambilla, D. &amp; Leroux, J. C. Is 3D printing of pharmaceuticals a disruptor or enabler? Adv. Mater.31(5), 1805680. 10.1002/adma.201805680 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30506794</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandekar, A. et al. 3D printing technology: A new milestone in the development of pharmaceuticals. Curr. Pharm. Des.25(9), 937–945 .</Citation><ArticleIdList><ArticleId IdType="pubmed">31339069</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadher, K., Trivedi, R., Wankhede, N., Kale, M. &amp; Umekar, M. 3D printing in pharmaceuticals: An emerging technology full of challenges. Ann. Pharm. Fr.79(2), 107–118. 10.1016/j.pharma.2020.08.007 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32853575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuźmińska, M. et al. Solvent-free temperature-facilitated direct extrusion 3D printing for pharmaceuticals. Int. J. Pharm.598, 120305. 10.1016/j.ijpharm.2021.120305 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33540022</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui, X. et al. Advances in extrusion 3D bioprinting: A focus on multicomponent hydrogel-based bioinks. Adv. Healthc. Mater.9(15), 1901648. 10.1002/adhm.201901648 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32352649</ArticleId></ArticleIdList></Reference><Reference><Citation>Heshmati Aghda, N. et al. Novel 3D printing particulate manufacturing technology for encapsulation of protein therapeutics: Sprayed Multi Adsorbed-Droplet Reposing Technology (SMART). Bioengineering9(11), 653. 10.3390/bioengineering9110653 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9687125</ArticleId><ArticleId IdType="pubmed">36354564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J. et al. 3D Bioprinted microparticles: Optimizing loading efficiency using advanced DoE technique and machine learning modeling. Int. J. Pharm.628, 122302. 10.1016/j.ijpharm.2022.122302 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36261096</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakka, J. &amp; Maniruzzaman, M. A proof-of-concept preparation of lipid-plasmid DNA particles using novel extrusion based 3D printing technology, SMART. Mol. Pharmaceutics12, 6504–6508 (2023). 10.1021/acs.molpharmaceut.3c00783 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37931027</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattari, A., Hanafizadeh, P. &amp; Hoorfar, M. Multiphase flow in microfluidics: From droplets and bubbles to the encapsulated structures. Adv. Colloid Interface Sci.282, 102208. 10.1016/j.cis.2020.102208 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32721624</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran, J. et al. Microreactor-based micro/nanomaterials: Fabrication, advances, and outlook. Mater. Horiz.10(7), 2343–2372. 10.1039/D3MH00329A (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37139613</ArticleId></ArticleIdList></Reference><Reference><Citation>Pumera, M., Nanomaterials meet &amp; microfluidics. Chem. Commun.47(20), 5671–5680. 10.1039/C1CC11060H (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21468401</ArticleId></ArticleIdList></Reference><Reference><Citation>Nightingale, A. M. et al. Large-scale synthesis of nanocrystals in a multichannel droplet reactor. J. Mater. Chem. A1(12), 4067–4076. 10.1039/C3TA10458C (2013).</Citation></Reference><Reference><Citation>Zhang, M. et al. Influencing factors and strategies of enhancing nanoparticles into tumors in vivo. Acta Pharm. Sin B11(8), 2265–2285. 10.1016/j.apsb.2021.03.033 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8424218</ArticleId><ArticleId IdType="pubmed">34522587</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsiftsoglou, A. S. Erythropoietin (EPO) as a key regulator of erythropoiesis, Bone Remodeling and endothelial transdifferentiation of multipotent mesenchymal stem cells (MSCs): Implications in regenerative medicine. Cells10(8), 2140. 10.3390/cells10082140 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8391952</ArticleId><ArticleId IdType="pubmed">34440909</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>